Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect of GS-248 Formulations in Healthy Subjects
NCT04617509Phase 1Completed
- Sponsor
- Gesynta Pharma
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vipoglanstat in systemic sclerosis (SSc) (3 arms), sponsored by Gesynta Pharma. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to infinity and 5 more. Started Mar 2020; status: completed.
02
Drugs
vipoglanstat
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT04617509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617509.